Thermo Fisher Scientific Inc.
TMO | NYSE
$656.02
+$4.57 (+0.70%)
Sep 21, 2026, 11:20 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 44.56B | 42.88B | 42.86B | 44.92B | 39.21B | 32.22B |
Cost of Revenue | 27.78B | 25.15B | 25.66B | 25.9B | 19.58B | 16.19B |
Gross Profit | 16.78B | 17.73B | 17.19B | 19.01B | 19.63B | 16.03B |
Operating Income | 8.11B | 7.66B | 7.45B | 8.53B | 10.32B | 7.9B |
Interest Income | 993M | 1.08B | 879M | 272M | 43M | 65M |
Pretax Income | 7.27B | 7B | 6.24B | 7.66B | 8.84B | 7.23B |
Net Income | 6.74B | 6.34B | 6B | 6.95B | 7.73B | 6.38B |
Selling & General & Admin | 7.27B | 8.68B | 8.41B | 9.02B | 7.91B | 6.95B |
Research & Development | 1.4B | 1.39B | 1.34B | 1.47B | 1.41B | 1.18B |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 8.67B | 10.07B | 9.75B | 10.49B | 9.32B | 8.13B |
Interest Expense | 1.42B | 1.65B | 1.49B | 726M | 536M | 553M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 36.45B | 35.22B | 35.41B | 36.39B | 28.89B | 24.32B |
Income Tax Expense | 547M | 657M | 284M | 703M | 1.11B | 850M |
Shares Outstanding (Basic) | 376M | 382M | 386M | 392M | 394M | 396M |
Shares Outstanding (Diluted) | 377M | 383M | 388M | 394M | 397M | 399M |
EPS (Basic) | 17.77 | 16.58 | 15.53 | 17.73 | 19.61 | 16.10 |
EPS (Diluted) | 17.74 | 16.53 | 15.45 | 17.64 | 19.46 | 15.98 |
EBITDA | 11.47B | 11.8B | 11.2B | 11.94B | 11.97B | 10.11B |
EBIT | 8.69B | 8.69B | 7.79B | 8.56B | 9.38B | 7.78B |
Depreciation & Amortization | 2.78B | 3.11B | 3.41B | 3.38B | 2.59B | 2.33B |
Add to Watchlist
Select watchlists to add or remove TMO